Power Law company profile

Akero Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2017 · IPO 2019 Unicorn

Innovative therapies targeting metabolic liver disease

Valuation

$3.76B

Market cap · 2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

11 investors on Akero Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage

Atlas Venture

Versant Ventures

venBio Partners

Apple Tree Partners

Series B+ 7 investors entered at this stage

Redmile Group

Rock Springs Capital

Boxer Capital

Cormorant Asset Management

BVF Partners

LifeSci Venture Partners

Janus Henderson Investors

Global footprint

Where Akero Therapeutics has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States98.4%

🇮🇳 India1.6%

2 countries shown

Web traffic by country

10K monthly visits
across markets

🇺🇸 United States83%

🇬🇧 United Kingdom13%

🇮🇳 India6%

Top 3 markets shown

Patent intelligence

$116k patent portfolio · 5 active families

Estimated portfolio value

$116k

<0.01% of market cap · 4506.6× smaller than top peer ChemoCentryx ($524M)

5 active patent families

Where Akero Therapeutics innovates PlungerMedical treatmentMechanical engineeringMechanicsMedical device

Where Akero Therapeutics concentrates vs peers

Each axis is a top-10 topic across Akero Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Akero Therapeutics

An AI-synthesized read of the highest-engagement posts about Akero Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Akero Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles